Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors.

Anforth R, Tembe V, Blumetti T, Fernandez-Peñas P.

Pigment Cell Melanoma Res. 2012 Sep;25(5):569-72. doi: 10.1111/j.1755-148X.2012.01031.x. Epub 2012 Aug 6.

PMID:
22726224
2.

Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors.

Anforth R, Blumetti TC, Clements A, Kefford R, Long GV, Fernandez-Peñas P.

Br J Dermatol. 2013 Dec;169(6):1310-3. doi: 10.1111/bjd.12519.

PMID:
23870055
3.

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.

Oberholzer PA, Kee D, Dziunycz P, Sucker A, Kamsukom N, Jones R, Roden C, Chalk CJ, Ardlie K, Palescandolo E, Piris A, MacConaill LE, Robert C, Hofbauer GF, McArthur GA, Schadendorf D, Garraway LA.

J Clin Oncol. 2012 Jan 20;30(3):316-21. doi: 10.1200/JCO.2011.36.7680. Epub 2011 Nov 7.

4.

COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors.

Escuin-Ordinas H, Atefi M, Fu Y, Cass A, Ng C, Huang RR, Yashar S, Comin-Anduix B, Avramis E, Cochran AJ, Marais R, Lo RS, Graeber TG, Herschman HR, Ribas A.

Mol Oncol. 2014 Mar;8(2):250-60. doi: 10.1016/j.molonc.2013.11.005. Epub 2013 Dec 1.

5.

Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern?

Lacouture ME, O'Reilly K, Rosen N, Solit DB.

J Clin Oncol. 2012 Jan 20;30(3):329-30. doi: 10.1200/JCO.2011.38.2895. Epub 2011 Nov 7. No abstract available.

6.

Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy.

Anforth R, Menzies A, Byth K, Carlos G, Chou S, Sharma R, Scolyer RA, Kefford R, Long GV, Fernandez-Peñas P.

J Am Acad Dermatol. 2015 May;72(5):809-15.e1. doi: 10.1016/j.jaad.2015.01.018. Epub 2015 Mar 3.

PMID:
25748298
7.

[Adverse skin reactions induced by BRAF inhibitors: a systematic review].

Sibaud V, Lamant L, Maisongrosse V, Delord JP.

Ann Dermatol Venereol. 2013 Aug-Sep;140(8-9):510-20. doi: 10.1016/j.annder.2013.02.031. Epub 2013 Jun 19. Review. French.

PMID:
24034635
8.

BRAF and RKIP are significantly decreased in cutaneous squamous cell carcinoma.

Zaravinos A, Kanellou P, Baritaki S, Bonavida B, Spandidos DA.

Cell Cycle. 2009 May 1;8(9):1402-8. Epub 2009 May 26.

PMID:
19342899
10.

Paradoxical oncogenesis: are all BRAF inhibitors equal?

Menzies AM, Kefford RF, Long GV.

Pigment Cell Melanoma Res. 2013 Sep;26(5):611-5. doi: 10.1111/pcmr.12132. Epub 2013 Jul 19.

PMID:
23795808
11.

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford RF.

J Clin Oncol. 2011 Apr 1;29(10):1239-46. doi: 10.1200/JCO.2010.32.4327. Epub 2011 Feb 22.

12.

Squamoproliferative lesions arising in the setting of BRAF inhibition.

Harvey NT, Millward M, Wood BA.

Am J Dermatopathol. 2012 Dec;34(8):822-6. doi: 10.1097/DAD.0b013e3182604873.

PMID:
22771896
13.

Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway.

Huang V, Hepper D, Anadkat M, Cornelius L.

Arch Dermatol. 2012 May;148(5):628-33. doi: 10.1001/archdermatol.2012.125.

PMID:
22431713
14.

Prevalence of human papillomavirus DNA in cutaneous neoplasms from renal allograft recipients supports a possible viral role in tumour promotion.

Stark LA, Arends MJ, McLaren KM, Benton EC, Shahidullah H, Hunter JA, Bird CC.

Br J Cancer. 1994 Feb;69(2):222-9.

15.

Cutaneous effects of BRAF inhibitor therapy: a case series.

Mattei PL, Alora-Palli MB, Kraft S, Lawrence DP, Flaherty KT, Kimball AB.

Ann Oncol. 2013 Feb;24(2):530-7. doi: 10.1093/annonc/mds292. Epub 2012 Oct 3.

16.

Is it good or bad to find a BRAF mutation?

Flaherty KT.

J Clin Oncol. 2011 Apr 1;29(10):1229-30. doi: 10.1200/JCO.2010.34.0497. Epub 2011 Feb 22. No abstract available.

17.

RAF inhibition and induction of cutaneous squamous cell carcinoma.

Robert C, Arnault JP, Mateus C.

Curr Opin Oncol. 2011 Mar;23(2):177-82. doi: 10.1097/CCO.0b013e3283436e8c. Review.

PMID:
21192261
18.

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.

Rubinstein JC, Sznol M, Pavlick AC, Ariyan S, Cheng E, Bacchiocchi A, Kluger HM, Narayan D, Halaban R.

J Transl Med. 2010 Jul 14;8:67. doi: 10.1186/1479-5876-8-67.

19.

RAF around the edges--the paradox of BRAF inhibitors.

Weeraratna AT.

N Engl J Med. 2012 Jan 19;366(3):271-3. doi: 10.1056/NEJMe1111636. No abstract available.

PMID:
22256810
20.

Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population.

Hsieh LL, Er TK, Chen CC, Hsieh JS, Chang JG, Liu TC.

Clin Chim Acta. 2012 Oct 9;413(19-20):1605-11. doi: 10.1016/j.cca.2012.04.029. Epub 2012 May 8.

PMID:
22579930
Items per page

Supplemental Content

Write to the Help Desk